Abstract:Platelet-type von Willebrand disease (vWD) and pseudo-vWD are two recently described intrinsic platelet defects characterized by enhanced ristocetin-induced agglutination in platelet-rich plasma. A similar finding is also typical of type IIB vWD, where it has been related to a von Willebrand factor (vWF) rather than a platelet abnormality. Platelet aggregation induced by unmodified human vWF in the absence of other stimuli has been reported in pseudo-vWD. In this study we demonstrate that vWF induces aggregation in platelet-type but not type IIB vWD. Aggregation is observed when normal plasma cryoprecipitate or purified vWF are added to platelet-rich plasma. Cryoprecipitate also aggregates washed platelets, although at higher concentrations than required for platelet-rich plasma. Purified vWF, however, induces significant aggregation of washed platelets only when plasma is added. EDTA inhibits vWF-induced aggregation. Its effect can be overcome by calcium but much less effectively by magnesium ions. Unstimulated platelets in platelet-rich plasma from patients with platelet-type but not type IIB vWD bind 125I-vWF in a specific and saturable manner. All different sized multimers of vWF become associated with platelets. Both aggregation and binding exhibit a similar vWF concentration dependence, suggesting that a correlation exists between these two events. Removal of ADP by appropriate consuming systems is without effect upon such binding or upon vWF-induced aggregation. Thrombin-induced 125I-vWF binding to washed platelets is normal in platelet-type as well as type IIB vWD. These results demonstrate that a specific binding site for unmodified human vWF is exposed on unstimulated platelets in platelet-type vWD. The relatively high vWF concentrations required for aggregation and binding may explain the lack of significant in vivo aggregation and thrombocytopenia in these patients. Moreover, these studies provide additional evidence that platelet-type and type IIB vWD are different diseases with distinct pathogeneses.

Platelet-type von Willebrand's disease: characterization of a new bleeding disorder

Platelet-Type von Willebrand Disease: New Insights into the Molecular Pathophysiology of a Unique Platelet Defect

Further characterization of platelet-type von Willebrand's disease in Japan

Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder

von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease.

Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet-type von Willebrand disease.

Mechanisms of thrombocytopenia in platelet-type von Willebrand disease

Visualizing the Von Willebrand Factor/glycoprotein Ib-IX Axis with a Platelet-Type Von Willebrand Disease Mutation.

Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor

[Biology of von Willebrand factor and pathogenesis of von Willebrand disease]

Diagnosis of platelet-type von Willebrand disease by flow cytometry

von Willebrand disease

A rare case of acquired von Willebrand syndrome type 2B: diagnosis, treatment, and underlying pathophysiology

Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy

Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias

Frequency of Platelet type versus Type 2B von Willebrand Disease

Genotyping and phenotyping of platelet function disorders

Phenotypic approaches to gene mapping in platelet function disorders

A novel frameshift GP1BB mutation causes autosomal dominant macrothrombocytopenia with decreased vWF receptor expression but normal platelet aggregation

Von Willebrand factor deficiency and atherosclerosis

Advances in our understanding of the molecular basis of disorders of platelet function